The Latin America, Middle East and Africa Inhalation Capsules Market would witness market growth of 7.8% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Inhalation Capsules Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $36.4 Million by 2031. The Argentina market is showcasing a CAGR of 8.4% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 7.4% during (2024 - 2031).
The focus on respiratory health and disease management is a significant catalyst for the growth of the inhalation capsules market by driving awareness, improving treatment outcomes, and fostering innovation in inhalation therapy. As respiratory diseases pose significant health challenges, the demand for effective and patient-friendly treatment options delivered via inhalation capsules will remain robust.
Additionally, one of the primary drivers behind the growth of the inhalation capsules market is the continuous innovation in inhalation device technologies. Manufacturers are developing advanced DPIs with improved drug delivery efficiency, dose accuracy, and patient convenience. These innovations include integrating smart features such as dose counters, feedback mechanisms, and connectivity options, allowing for better medication adherence and monitoring. Developing novel formulations and combination therapies delivered via inhalation capsules further expands the therapeutic options available to patients, driving market growth.
In the LAMEA region, the demand for inhalation capsules is rising, driven by various factors unique to each country. Brazil, for instance, boasts the largest healthcare sector in Latin America, allocating a significant portion of its GDP, around 9.47% or US$161 billion, to healthcare. Hence, the evolving healthcare landscape drives the rising demand for inhalation capsules in the LAMEA region.
Based on Type, the market is segmented into Gelatin Capsules, and Hypromellose Capsules. Based on Application, the market is segmented into Asthma Treatment, COPD Management, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Inhalation Capsules Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $36.4 Million by 2031. The Argentina market is showcasing a CAGR of 8.4% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 7.4% during (2024 - 2031).
The focus on respiratory health and disease management is a significant catalyst for the growth of the inhalation capsules market by driving awareness, improving treatment outcomes, and fostering innovation in inhalation therapy. As respiratory diseases pose significant health challenges, the demand for effective and patient-friendly treatment options delivered via inhalation capsules will remain robust.
Additionally, one of the primary drivers behind the growth of the inhalation capsules market is the continuous innovation in inhalation device technologies. Manufacturers are developing advanced DPIs with improved drug delivery efficiency, dose accuracy, and patient convenience. These innovations include integrating smart features such as dose counters, feedback mechanisms, and connectivity options, allowing for better medication adherence and monitoring. Developing novel formulations and combination therapies delivered via inhalation capsules further expands the therapeutic options available to patients, driving market growth.
In the LAMEA region, the demand for inhalation capsules is rising, driven by various factors unique to each country. Brazil, for instance, boasts the largest healthcare sector in Latin America, allocating a significant portion of its GDP, around 9.47% or US$161 billion, to healthcare. Hence, the evolving healthcare landscape drives the rising demand for inhalation capsules in the LAMEA region.
Based on Type, the market is segmented into Gelatin Capsules, and Hypromellose Capsules. Based on Application, the market is segmented into Asthma Treatment, COPD Management, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Market Report Segmentation
By Type- Gelatin Capsules
- Hypromellose Capsules
- Asthma Treatment
- COPD Management
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. LAMEA Inhalation Capsules Market by Type
Chapter 6. LAMEA Inhalation Capsules Market by Application
Chapter 7. LAMEA Inhalation Capsules Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Methodology
LOADING...
